Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Gri Bio Inc (GRI)

Gri Bio Inc (GRI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,611
  • Shares Outstanding, K 8,933
  • Annual Sales, $ 0 K
  • Annual Income, $ -13,040 K
  • EBIT $ -7 M
  • EBITDA $ -5 M
  • 60-Month Beta -2.04
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.06
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -11.57
  • Most Recent Earnings $-0.67 on 11/14/24
  • Next Earnings Date 11/12/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.40
  • Number of Estimates 1
  • High Estimate -0.40
  • Low Estimate -0.40
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.04%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.6113 +21.05%
on 12/03/24
0.9950 -25.63%
on 12/11/24
+0.1010 (+15.81%)
since 11/20/24
3-Month
0.3015 +145.44%
on 10/01/24
1.7900 -58.66%
on 10/21/24
+0.2992 (+67.88%)
since 09/20/24
52-Week
0.3015 +145.44%
on 10/01/24
65.0000 -98.86%
on 01/30/24
-36.1059 (-97.99%)
since 12/20/23

Most Recent Stories

More News
GRI Bio to Participate in the Virtual Investor Closing Bell Series

GRI : 0.7400 (-3.90%)
GRI Bio Presents Positive Preclinical Data on GRI-0621 for Treating Pulmonary Fibrosis at AFDD Summit

GRI Bio presented preclinical data on GRI-0621, showing its potential to treat idiopathic pulmonary fibrosis by inhibiting iNKT cell activity.Quiver AI SummaryGRI Bio, Inc. presented positive preclinical...

GRI : 0.7400 (-3.90%)
GRI Bio Showcases GRI-0621’s Potential to Reduce Inflammation, Type 1 Cytokines and Reduce Hepatic Fibrosis in Idiopathic Pulmonary Fibrosis (IPF)

GRI : 0.7400 (-3.90%)
GRI Bio, Inc. Reports $13.9 Million in Gross Proceeds and Provides Update on GRI-0621 Phase 2a Study for IPF Treatment

GRI Bio raised $13.9 million, extending its cash runway for GRI-0621's Phase 2a study in idiopathic pulmonary fibrosis.Quiver AI SummaryGRI Bio, Inc. announced it has raised $13.9 million in gross proceeds...

GRI : 0.7400 (-3.90%)
GRI Bio Reports Third Quarter 2024 Financial Results and Outlines Progress Towards Clinical Data Readout of GRI-0621 in Ongoing Phase 2a Study for Idiopathic Pulmonary Fibrosis

GRI : 0.7400 (-3.90%)
GRI Bio Raises a Total of $13.9 Million in Gross Proceeds Since the Beginning of 2024

GRI : 0.7400 (-3.90%)
GRI Bio Announces Exercise of Warrants

GRI : 0.7400 (-3.90%)
GRI Bio Presents Positive Preclinical Data Demonstrating GRI-0621’s Ability to Inhibit Invariant Natural Killer T (iNKT) Cell Activity and Reduce Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis (IPF)

GRI : 0.7400 (-3.90%)
GRI Bio to Present at the 22nd International Colloquium on Lung and Airway Fibrosis

GRI : 0.7400 (-3.90%)
JTC Team Announces Presenting Company Line Up for the Virtual Investor “Ask the CEO” Conference Being Held October 24-25, 2023

- Live video webcast interactive Q&A with participating companies -

EVFM : 0.0094 (-4.08%)
GRI : 0.7400 (-3.90%)
MBRX : 1.6700 (-7.73%)
XBIO : 4.29 (+0.23%)
AREC : 1.0700 (+0.94%)
CNSP : 0.1080 (-1.82%)
NVNO : 2.49 (-1.58%)
PALI : 1.7500 (-2.78%)

Business Summary

GRI Bio Inc. is a clinical stage biopharmaceutical company which focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. GRI Bio Inc., formerly known as Vallon Pharmaceuticals Inc., is based in PHILADELPHIA, PA.

See More

Key Turning Points

3rd Resistance Point 0.8233
2nd Resistance Point 0.8067
1st Resistance Point 0.7733
Last Price 0.7400
1st Support Level 0.7233
2nd Support Level 0.7067
3rd Support Level 0.6733

See More

52-Week High 65.0000
Fibonacci 61.8% 40.2852
Fibonacci 50% 32.6507
Fibonacci 38.2% 25.0163
Last Price 0.7400
52-Week Low 0.3015

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar